Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers
NCT ID: NCT04304547
Last Updated: 2020-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2020-02-04
2020-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
NCT04083846
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348
NCT04660370
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)
NCT04883658
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
NCT05192356
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions
NCT06399068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
Subject of sequence A takes IP in the following order:
1. Each tablet of CKD-828 and D097 and D337 be taken at once
2. CKD-348 T1 1 tablet
3. CKD-348 T2 1 tabet
Sequence B
CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Subject of sequence B takes IP in the following order:
1. CKD-348 T1 1 tablet
2. CKD-348 T2 1 tablet
3. Each tablet of CKD-828 and D097 and D337 be taken at once
Sequence C
CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Subject of sequence C takes IP in the following order:
1. CKD-348 T2 1 tablet
2. Each tablet of CKD-828 and D097 and D337 be taken at once
3. CKD-348 T1 1 tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
Subject of sequence A takes IP in the following order:
1. Each tablet of CKD-828 and D097 and D337 be taken at once
2. CKD-348 T1 1 tablet
3. CKD-348 T2 1 tabet
CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Subject of sequence B takes IP in the following order:
1. CKD-348 T1 1 tablet
2. CKD-348 T2 1 tablet
3. Each tablet of CKD-828 and D097 and D337 be taken at once
CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Subject of sequence C takes IP in the following order:
1. CKD-348 T2 1 tablet
2. Each tablet of CKD-828 and D097 and D337 be taken at once
3. CKD-348 T1 1 tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Health Volunteers
3. Subject who agreeds to participate in this clinical trial voluntarily
Exclusion Criteria
19 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jae Yong Chung
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A86_04BE1913P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.